Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Qingqiao Granules (also known as Xiaoer Jinqiao Granules) is a traditional Chinese medicine (TCM) patent herbal preparation developed and manufactured by Sichuan Defeng Pharmaceutical, a subsidiary of Yifan Pharmaceutical. Formulated specifically for pediatric use, it contains a mixture of herbal extracts including Lonicerae Flos (Shanyinhua), Forsythiae Fructus (Lianqiao), Puerariae Lobatae Radix (Fenge), Isatidis Folium (Daqingye), Sophorae Tonkinensis Radix et Rhizoma (Shandougen), Bupleuri Radix (Chaihu), and Glycyrrhizae Radix et Rhizoma (Gancao). Xiaoer Qingqiao Granules is indicated for the treatment of pediatric influenza, acute tonsillitis, and acute upper respiratory tract infections, particularly for relieving symptoms such as fever, aversion to cold, sore throat, dry throat, and pharyngeal burning. It is recommended in clinical guidelines for pediatric influenza in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Qingqiao Granules.